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Abstract
Introduction: HIV-controllers have the ability to spontaneously maintain viraemia at low or undetectable levels in the absence
of antiretroviral treatment. Furthermore, HIV-controllers seem to have a superior capacity to spontaneously clear hepatitis C
virus (HCV) compared to non HIV-controllers. Some of these subjects eventually lose HIV-controller status (transient con-
trollers), whereas some HIV-controllers show a persistent natural HIV control (persistent controllers). We aimed to analyse
whether persistent controllers have superior capacity to spontaneously clear HCV compared to transient controllers.
Methods: We recruited HIV-controllers from January 1981 up to October 2016 with available antibodies to HCV (anti-HCV)
data (n = 744). Factors associated with HIV spontaneous control in relation to HCV status were analysed in persistent and
transient HIV-controllers with anti-HCV positive (n = 202 and n = 138 respectively) in comparison with 1700 HCV positive
non HIV-controllers recruited from January 1981 up to March 2018, bivariate and multivariate analyses, following a logistic
regression model, were applied. In addition, the factors related to the loss and time to lose HIV-controller status were
explored (n = 744) using Log rank test and Kaplan–Meier curves, in this case the multivariate analysis consisted in a Cox
regression model.
Results: A higher frequency of HCV spontaneous clearance was found in persistent HIV-controllers (25.5%) compared to non-
controllers (10.2%). After adjusting for potential confounders, as sex, age, HIV transmission risk, CD4+ T-cell nadir and time of
follow-up, HCV clearance was independently associated with persistent HIV spontaneous control (p = 0.002; OR (95%
CI) = 2.573 (1.428 to 4.633)), but not with transient spontaneous control (p = 0.119; 1.589 (0.888 to 2.845)). Furthermore,
persistent HIV-controllers were more likely to spontaneously clear the HCV in comparison with transient controllers
(p = 0.027; 0.377 (0.159 to 0.893). Finally, not to lose or lengthen the time of losing this control was independently associated
with HCV spontaneous clearance (p = 0.010; 0.503 (0.297 to 0.850).
Conclusions: This study shows an association between spontaneous persistent HIV-control and HCV spontaneous clearance.
The study findings support the idea of preserved immune mechanisms in persistent HIV control implicated in HCV sponta-
neous clearance. These results highlight persistent HIV-controllers but not transient controllers as a good model of functional
HIV cure.
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1 | INTRODUCTION
HIV-controllers are a small group of subjects (<1%) that main-
tain low (viraemic controllers) or undetectable (elite
controllers) HIV viral load (VL) in the absence of antiretroviral
treatment [1]. In large cohort studies [2,3], it is clear that this
phenotype is heterogeneous with some HIV-controllers even-
tually losing the spontaneous viral control capacity, these
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individuals are named transient controllers as opposed to per-
sistent controllers [4]. Understanding the mechanisms
involved in this phenomenon is quite important. On one hand
factors associated with the loss of HIV-controller status may
assist giving an optimum clinical care to these individuals and
reciprocally, persistent controllers may serve as a good model
for functional HIV cure. The mechanisms and attributes of this
extraordinary phenotype of exceptionally long-term control
are still not completely understood [5-7]. Recent studies show
that persistent HIV-controllers in comparison with transient
controllers have higher levels of HIV-specific T-cell response,
low viral evolution, low levels of inflammation and a peculiar
proteomic and metabolomic profile [4,8,9].
On the other hand, HIV-controllers as a whole seem to
have a higher capacity to spontaneously clear hepatitis C virus
(HCV) compared to non HIV-controllers [10,11], although
other studies have not found this enhanced capacity [12,13].
Besides, it remains unknown whether persistent HIV-con-
trollers have a higher capacity to spontaneously clear HCV.
According to the improved immunological capacities men-
tioned earlier, we hypothesize that persistent HIV-controllers
may have a better ability to spontaneously clear HCV. These
findings could lead to significant advances on the chronic viral
infections therapeutically designs as they act as an additional
attribute of the persistent HIV-controllers as a model for a
HIV functional cure.
In this study we have been able to investigate HCV status
profile in the large cohort of HIV-controllers of the Spanish
AIDS Research Network (ECRIS). Thus, the aim of this study
was to analyse whether persistent HIV-controllers had supe-
rior capacity to spontaneously clear HCV compared to tran-
sient HIV-controllers.
2 | METHODS
2.1 | Patients and variables
Patients’ clinical and epidemiological data were included in the
cohort of HIV-controllers of the AIDS Research Network
(ECRIS). This is an open, multicentre cohort of HIV controllers
whose data come from the Long-Term Non-Progressors
cohort and the Cohort of the Spanish AIDS Research Network
(CoRIS) [14,15] and other clinical centres across Spain. This
cohort has been previously published [3,16]. See Annex S1 for
participating centres. In the last update, October 2016, this
cohort included 807 HIV-controllers.
This is a retrospective cohort study. Inclusion criteria were
patients with VL < 2000 HIV RNA copies/mL ((elite con-
trollers, VLs below the detection limit [<50 HIV-RNA copies/
mL], n = 273) and viraemic controllers (controllers with VLs
between 50 and 2000 HIV-RNA copies/mL, n = 471)) in the
absence of antiretroviral treatment for at least one year of
follow-up and with available antibodies to HCV (anti-HCV)
data (n = 744). HIV-controllers were split into “Transient HIV-
controllers” (n = 333), subjects who lost HIV-controller status
defined as loss of virological control (first viral measurement
of a sustained increase of >2000 HIV RNA copies/mL during
more than one year of follow-up) or initiation of an antiretro-
viral treatment, as previously reported [16]. The same criteria
were applied for the loss of elite controller status but with a
sustained increase of >50 HIV RNA copies/mL during more
than one year. Subjects without loss of HIV-controller status
were defined as “Persistent HIV-controllers” (n = 411). HCV
spontaneous clearers were defined as patients exposed to
HCV (anti-HCV positive) with qualitative negative HCV PCR
in the absence of HCV specific treatment. These three data
(anti-HCV positive, HCV PCR and HCV specific treatment)
must be available to classify a patient as a HCV spontaneous
clearer.
For the analysis of the factors associated with persistent
and transient HIV spontaneous control based on HCV pro-
file, we selected HCV exposed persistent (n = 202) and tran-
sient (n = 138) HIV-controllers and non HIV-controllers
(n = 1700). HCV exposed HIV non-controllers were subjects
with consecutive visits to the Infectious Disease Unit at Vir-
gen del Rocıo University Hospital (Seville, Spain) from Jan-
uary 1981 up to March 2018. These subjects were
administered ART based on clinical criteria of contemporary
guidelines.
For the analysis of factors associated with the loss of HIV
spontaneous control we used the complete HIV ECRIS cohort
(n = 744) with available anti-HCV data. In addition, we per-
formed the analysis of variables associated with the time to
lose HIV-controller status. The time to lose HIV-controller sta-
tus was considered the time period between the HIV diagno-
sis and the loss of HIV-controller status. The subjects who did
not lose HIV-controller status were censored in the last fol-
low-up point.
All subjects gave written informed consent in accordance
with the Declaration of Helsinki. The protocol was approved
by the Comite de Etica de la Investigacion at the Hospital
Universitario Virgen del Rocıo de Sevilla (2012PI/240).
Routinely, the absolute numbers of CD4+ T cells were
assayed from fresh whole blood samples, using the Epics XL-
MCL flow cytometer (Beckman Coulter). Plasma HIV RNA
load was measured in fresh samples by quantitative poly-
merase chain reaction (PCR; COBAS Ampliprep/COBAS Taq-
man HIV test; Roche molecular systems), according to the
manufacturer’s instructions. The detection limit was 50 HIV
RNA copies/mL. Qualitative and quantitative reverse tran-
scription PCR was performed for plasma HCV RNA amplifica-
tion (COBAS Amplicor; Roche Diagnosis, Barcelona, Spain),
with detection limit of 15 IU/mL. HCV genotype was deter-
mined using a reverse-hybridization assay (InnoLIPA HCV II;
Innogenetics, Barcelona, Spain).
2.2 | Statistical analysis and Covariates
Continuous variables were expressed as median and
interquartile range (IQR) and categorical variables were
expressed as number and percentage. Bivariate and multi-
variate analyses, following a logistic regression model, were
applied for the analysis of factors associated with persistent
and transient HIV spontaneous control and for the analysis
of factors associated with loss of HIV-controller status. For
these two analyses the dependent variables were being HIV-
controller (persistent and transient) and loss of HIV-control
respectively. For the analysis of time to lose HIV-controller
status, the time to lose this condition was considered the
dependent variable, Log rank test and Kaplan–Meier curves
were used. In this case the multivariate analysis consisted in
a Cox regression model, using the enter procedure. As
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covariates these models were adjusted by sex, age at HIV
diagnosis, time of follow-up, people who inject drugs as
(PWID) as risk of HIV transmission, CD4+ T-cell nadir, HLA-
B*57 typing, and finally by HIV elite-controller status and
HCV spontaneous clearance (as describe earlier), as potential
confounders. All variables with a p < 0.1 were included in
the multivariate analysis, and p < 0.05 was considered statis-
tically significant. Statistical analyses were performed using
SPSS software version 22 (IBM SPSS, Chicago, Illinois) and
graphs were generated with Prism, version 6.0 (GraphPad
Software, Inc.).
3 | RESULTS
3.1 | Higher frequency of HCV spontaneous
clearance in persistent HIV-controllers, but not in
transient HIV-controllers, compared to non-
controllers
First, we found that the rate of HCV spontaneous clearance
in the overall HIV-controller population (n = 340) was higher
compared with non-controllers (n = 1700) (19.4% vs. 10.2%
respectively) confirming previous results in small cohorts
[10,11]. After adjusting for sex, age at HIV diagnosis, time of
follow-up and the risk of transmission  frequency of PWID
, as potential confounders, HCV spontaneous clearance
remained independently associated with HIV spontaneous
control (p < 0.001; 2.180 (1.472 to 3.229). Afterwards, we
compared HCV-exposed persistent (n = 202) and transient
HIV-controllers (n = 138) with the 1700 HCV positive HIV
non-controllers (Table 1). We found that in both groups there
was a higher proportion of women, higher nadir CD4+ T-cell
levels, lower frequency of patients at clinical stage CDC C, a
higher representation of HCV genotype 3 and a lower repre-
sentation of genotype 1 and, as expected, an overrepresenta-
tion of HLA-B57 + subjects compared to HIV-non-controllers
(Table 1). However, persistent HIV-controllers presented
higher rates of HCV spontaneous clearance than HIV non-con-
trollers (25.5% vs. 10.2%), although this was not the case for
transient HIV-controllers (14.5% vs. 10.2%). After adjusting
for potential confounders, HCV spontaneous clearance
remained independently associated with persistent HIV spon-
taneous control but not with transient (Table 2). Due to the
scarce data, we could not adjust for HLA-B*57 typing, but it
was associated with both persistent and transient control
(Table 2).
When we restricted the analysis to persistent elite con-
trollers (n = 143) and transient elite controllers (n = 43)
(Table 3), again a higher frequency of HCV spontaneous
clearers was found in persistent elite controllers than in non-
controllers (20.6% vs. 10.2%) but not in transient elite con-
trollers ((11.1% vs. 10.2%) (p = 0.008; OR (95%) = 2.279
(1.240 to 4.189) and p = 0.860; OR (95%) = 1.099 (0.384 to
3.144) respectively). In the multivariate analysis, in a first
model after adjusting by sex, again, HCV spontaneous clear-
ance was associated with persistent elite HIV control
(p = 0.016; OR (95%) = 2.127 (1.149 to 3.938). In a second
model after adjusting by sex and CD4+ T-cell nadir levels this
correlation was lost (p = 0.123; OR (95%) = 1.749 (0.859 to
3.558).
3.2 | HCV spontaneous clearance was
independently associated with persistent
HIV-controller status
We analysed the whole HIV-controller subset in detail
(n = 744). Table 4 shows the differences between persistent
controllers and transient controllers. Persistent controllers
had longer time of follow-up, higher CD4 T-cell nadir and
higher frequency of elite control, PWID and HLA-B*57 carri-
ers than transient controllers. We also categorized patients
based on the calendar year of HIV diagnosis. Interestingly,
while there were more persistent controllers HIV-diagnosed
in the 80s decade, there were more transient controllers HIV-
diagnosed in the 2000s. It is important to note that there
were no differences in HCV genotype distribution between
groups (Table 4). These results point out that the loss of con-
trol was not associated with the different genotype distribu-
tion.
Regarding HCV profile, HIV persistent controllers had
higher frequency of anti-HCV positive than transient con-
trollers. Interestingly, there was a higher proportion of HCV
spontaneous clearers in persistent controllers. In a multivari-
ate analysis, the factors independently associated with loss of
HIV-controller status were lower CD4 T-cell nadir, non-elite
controller status and not achieving HCV spontaneous clear-
ance (table 5). We also adjusted by calendar year of HIV posi-
tive instead of by the time of follow-up, as these were co-
linear variables and similar results were found (data not
shown). We could not adjust simultaneously by HLA-B*57 and
spontaneous HCV clearance due to the low number of sub-
jects sharing both determinations. However, when we included
HLA-B*57 genotype in the previous model no association was
found between this variable and the loss of HIV-controller sta-
tus (p = 0.384; OR (95%) = 0.650 (0.247 to 1.714)).
The same results were obtained when the patients were
categorized based only on the loss of virological control, not
on the loss of HIV controller status (n = 563 and 181 respec-
tively). After adjusting by sex, time of follow-up and PWID,
again: CD4 T-cell nadir, the frequency of elite controllers and
HCV spontaneous clearance were independently associated
with not having loss virological control ((p < 0.001; OR
(95%) = 0.995 (0.993 to 0.997), p < 0.001; OR (95%) = 0.136
(0.068 to 0.274) and p = 0.027; OR (95%) = 0.377 (0.159 to
0.893) respectively)).
3.3 | HCV spontaneous clearance was associated
with the time to maintain HIV-controller status
Another way of analysing the results is to perform a time to
event analysis. The event was the loss of HIV-controller sta-
tus. The median time of follow-up was 7.2 [3.7 to 17.7] years.
The analysis revealed that younger age at diagnosis, PWID as
risk factor, high CD4+ T-cell nadir, being elite, HLA-B*57 carri-
ers and having cleared HCV spontaneously were associated
with maintaining HIV-controller status overtime (Figure 1).
After adjusting by all these variables, but HLA-B*57, in a Cox
regression model, having cleared HCV spontaneously was
independently associated with the time to maintain HIV-con-
troller status together with the rest of the variables men-
tioned earlier (Table 6). However, when we included HLA-
B*57 genotype in the previous model no association was
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Table 2. Factors associated with persistent and transient HIV spontaneous control
Variables
Persistent HIV-control Transient HIV-control
Adjusted p; OR (IC 95%) Adjusted p; OR (IC 95%)
HCV spontaneous clearance 0.002; 2.573 (1.428 to 4.633) 0.119; 1.589 (0.888 to 2.845)
Female sex 0.006; 2.176 (1.250 to 3.790) <0.001; 2.854 (1.823 to 4.467)
CD4 nadir <0.001; 1.009 (1.008 to 1.010) <0.001; 1.006 (1.005 to 1.007)
Time of follow-up NA 0.002; 0.961 (0.938 to 0.985)
HIV transmission risk, PWID NA 0.530; 0.855 (0.523 to 1.396)
p values < 0.05 are shown in bold. CI, confidence interval; NA, not applicable; OR, odd ratio, PWID, people who inject drug.














p; OR (CI95%) p; OR (CI95%)
Female sex (n) % 50/143 (35.0) 17/43 (39.5) 235/1700
(13.8)
<0.001; 3.352 (2.314 to 4.854) <0.001; 4.076 (2.178 to 7.628)
Age at HIV
diagnosis




115/143 (80.4) 32/43 (74.4) 1379/1700
(83.6)
0.332; 0.807 (0.523 to 1.245) 0.116; 0.572 (0.285 to 1.148)
PWID, female (n)
%





17.4 [8.1 to 22.6] 18.6 [11.8 to
24.9]
0.491; 1.007 (0.987 to 1.028) 0.094; 0.971 (0.938 to 1.005)
CD4 nadir 510 [363 to 680] 292 [220 to 420] 111 [31 to
224]
<0.001; 1.009 (1.008 to 1.011) <0.001; 1.005 (1.004 to 1.007)
Clinical stage C
(n) %a
7/72 (9.7) 3/41 (7.0) 275/1674
(16.4)
0.136; 0.548 (0.249 to 1.208) 0.131; 0.402 (0.123 to 1.310)
HCV PCR+ (n)
%b
76/90 (84.4) 38/42 (90.5) 1521/1694
(89.8)
0.110; 0.617 (0.342 to 1.115) 0.884; 1.081 (0.381 to 3.064)
HCV genotype detected (n) %c
Genotype 1 23/54 (42.6) 11/28 (39.3) 616/1075
(57.3)
0.036; 0.553 (0.318 to 0.961) 0.063; 0.482 (0.224 to 1.039)
Genotype 2 1/54 (1.9) 0/28 (0) 9/1075 (0.8) 0.450; 2.235 (0.278 to 17.956) 0.999
Genotype 3 16/54 (29.6) 13/28 (46.4) 237/1075 (22) 0.195; 1.489 (0.816 to 2.717) 0.004; 3.064 (1.438 to 6.530)
Genotype 4 14/54 (25.9) 4/28 (14.3) 213/1075
(19.8)




14/68 (20.6) 4/36 (11.1) 173/1694
(10.2)
0.008; 2.279 (1.240 to 4.189) 0.860; 1.099 (0.384 to 3.144)
HLA-B*57 (n) %e 25/64 (39.1) 3/20 (15.0) 41/818 (5) <0.001; 12.15 (6.72 to 22.00) 0.062; 3.344 (0.942 to 11.87)
p values < 0.1 are shown in bold. CI, confidence interval; NA, not applicable; OR, odd ratio; PWID, people who inject drug.
aClinical stage C data from 72 persistent HIV-controllers, 41 transient HIV-controllers and 1674 non-controllers; bHCV PCR+ was considered
before HCV treatment onset in those who were treated; cHCV genotype detected from 54 persistent HIV-controllers, 28 transient HIV-con-
trollers and 1075 non-controllers.
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found between this variable and the time to lose HIV-con-
troller status (p = 0.229; OR (95%) = 0.703 (0.396 to 1.249)).
4 | DISCUSSION
Results presented herein show that persistent HIV-controllers,
as opposed to what happened to transient HIV-controllers,
had a better ability to spontaneously clear HCV. In fact, the
time to lose HIV-controller status was associated with HCV
spontaneous clearance.
HIV-controller is a heterogeneous phenotype [2,3], some
HIV-controllers eventually lose HIV-controller status [17–19].
It is a key to detect these patients before the loss of control
takes place and differentiate them of the persistent HIV-con-
trollers. This will enable a correct treatment in transient HIV-
controllers to avoid non AIDS events, as cardiovascular dis-
eases [16,20,21] and, on the other hand, the persistent con-
trol phenotype will become a good model of persistent HIV-
remission in order to design immunotherapeutic strategies [7].
In this manuscript we describe a new characteristic of persis-
tent HIV-controllers as is a higher ability to spontaneously
clear HCV unlike transient controllers. Cohort studies are
needed to validate biomarkers associated with the loss of HIV
control, independently of HCV clearance status, to offer these
subjects therapeutic options, not necessarily cART [22].
HIV persistent controllers have been recently characterized
as having low levels of proviral diversity, low reservoir size
and high levels of HIV-specific T-cell polyfunctionality [4] asso-
ciated with a specific proteomic and metabolomic profile [8,9].
Many of these subjects were PWID and had multiple re-expo-
sures to HCV during the first years of being positive that
mainly occurred in the 80s and early 90s and anti-VHC and
Table 4. Characteristics of HIV-controllers stratified according to the loss of HIV control status
Persistent controllers (411) Transient controllers (n = 333) p; OR (IC 95%)
Female sex (n) % 114/417 (27.7) 111/333 (33.3) 0.099; 1.303 (0.952 to 1.783)
Age at HIV diagnosis 29 [24 to 35] 30 [25 to 36] 0.334; 1.008 (0.992 to 1.024)
Calendar year of HIV diagnosis
1980 to 1989 91/411 (22.1) 52/332 (15.7) 0.027; 0.653 (0.448 to 0.952)
1990 to 1999 99/411 (24.1) 94/332 (28.3) 0.192; 1.245 (0.896 to 1.729)
2000 to 2009 157/411 (38.2) 174/332 (52.4) <0.001; 1.782 (1.329 to 2.389)
2010 to 2015 64/411 (15.6) 12/332 (3.6) <0.001; 0.203 (0.108 to 0.384)
Time of follow-up (years)a 9.4 [4.1 to 19.1] 5.7 [3.0 to 14.7] <0.001; 0.960 (0.942 to 0.977)
HIV transmission risk, PWID (n) % 167/411 (40.6) 106/333 (31.8) 0.013; 0.682 (0.504 to 0.924)
CD4 T-cell nadir 550 [419 to 710] 327 [253 to 443] <0.001; 0.994 (0.993 to 0.995)
Clinical stage C (n) %b 7/296 (2.4) 12/305 (3.9) 0.277; 1.691 (0.656 to 4.356)
Elite HIV-controller status (n) % 207/411 (50.4) 66/333 (19.8) <0.001; 0.244 (0.175 to 0.339)
Anti-HCV+ (n, %) 202/411 (49.1) 138/333 (41.4) 0.036; 0.732 (0.547 to 0.980)
HCV PCR+ (n,%)c 99/332 (29.8) 113/325 (34.8) 0.175; 1.254 (0.904 to 1.741)
Log10 HCV VL (IU/mL)
d 5.85 [5.40 to 6.40] 6.07 [5.41 to 6.60] 0.289; 1.166 [0.878 to 1.550]
HCV genotype detected (n) %e
Genotype 1 28/70 (40) 37/84 (44) 0.613; 1.181 (0.620 to 2.248)
Genotype 2 2/70 (2.9) 3/84 (3.6) 0.804; 1.259 (0.204 to 7.756)
Genotype 3 23/70 (32.9) 31/84 (36.9) 0.600; 1.195 (0.613 to 2.329)
Genotype 4 17/70 (24.3) 13/84 (15.5) 0.172; 0.571 (0.255 to 1.277)
HCV clearance (n%)f 24/94 (25.5) 17/117 (14.5) 0.047; 0.496 (0.248 to 0.991)
HLA-B*57 (n) %g 31/105 (29.5) 15/96 (15.6) 0.021; 0.442 (0.221 to 0.883)
p values < 0.1 are shown in bold. CI, confidence interval; NA, not applicable; OR, odd ratio; PWID, people who inject drug.
aTime period between HIV diagnosis and loss of HIV-controller status or last monitored visit point; bclinical stage C data from 296 persistent con-
trollers, and 305 transient controllers; cHCV PCR data available for 332 persistent controllers and 325 transient controllers. HCV PCR+ was con-
sidered before HCV treatment onset in those who were treated; dHCV VL data from 96 persistent controllers and 101 transient controllers;
eHCV genotype detected in 70 persistent controllers, and 84 transient controllers; ffor HCV spontaneous clearance calculation we only considered
patients with anti-HCV+ and available data of HCV PCR and HCV treatment. HCV spontaneous clearance was calculated in 94 persistent con-
trollers and 117 transient controllers; gHLA-B*57 data from 105 persistent controllers, and 96 transient controllers.
Table 5. Factors associated with loss of HIV-controller status
Adjusted
p; OR (IC 95%)
Female sex 0.373; 1.382 (0.679 to 2.815)
Time of follow-up 0.328; 0.978 (0.936 to 1.022)
HIV transmission risk, PWID 0.149;1.767 (0.816 to 3.827)
CD4 T-cell nadir <0.001; 0.995 (0.993 to 0.997)
Elite HIV-controller status <0.001; 0.136 (0.068 to 0.274)
HCV spontaneous clearance 0.027; 0.377 (0.159 to 0.893)
p values < 0.05 are shown in bold. CI, confidence interval; OR, odd
ratio; PWID, people who inject drug.
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HCV RNA measurements were later available, if after all this
re-exposures the individual remained with negative ARN for
HCV tell us about the preserved ability of those subjects to
spontaneously clear the virus. We believe that independently
the individuals became positive with one virus before the
other, normally HCV precedes HIV positivity and the potential
re-exposures to HCV, it will be interesting to extent immuno-
logical correlates [23] of persistent HIV control and HCV
spontaneous clearance to deeply dissect the intrinsic host
mechanisms involved in this extraordinary phenotype. We
have recently found that these subjects, able to clear HCV
and spontaneously control HIV, referred as “supercontrollers,”
showed higher levels of HCV-specific CD4+ T-cell polyfunc-
tionality, higher levels of CD8 + CD161 T-cells together with
low T-cell exhaustion associated with preserved innate immu-
nity features [23]. This sustained immunity is also reflected in
the rates of HCV spontaneous clearance in these subjects
(25.5%) which is similar to that found in HCV monoinfected
patients in Spain (22%) [24]. Hence, supercontrollers, who are
enriched in persistent controllers, contribute with these mech-
anisms of sustained immunity to very long-term persistent
HIV remission.
Based on this study, the higher rates of HCV spontaneous
clearance among HIV-controllers, found previously in small
Figure 1. Kaplan–Meier curves for time to loose HIV-controller status analysis.Percent of subjects not losing HIV controller status are
shown for (A) Age dichotomized using the median (29.4 [24.6–35.4]) as the cut-off value, (B) people who inject drugs (PWID), (C) Nadir CD4+ T-
cell counts dichotomized using the median (447 [304–622]) as the cut-off value, (D) elite controller, (E) HCV spontaneous clearance and (F) carri-
ers of HLA*B57. Bivariate analysis using a Log-rank test was performed to assess significant differences among the curves.
Table 6. Factors associated with the time to lose HIV-controller status
Univariate
p; OR (IC 95%)
Adjusted
p; OR (IC 95%)
Female sex (n) % 0.831; 1.025 (0.816 to 1.288)
Age at HIV diagnosis >29.4 yearsa <0.001; 1.929 (1.541 to 2.416) <0.001; 2.301 (1.545 to 3.427)
HIV transmission risk, PWID (n) % <0.001; 0.262 (0.206 to 0.334) 0.016; 0.587 (0.380 to 0.906)
CD4 T-cell nadir >447 cells/mma <0.001; 0.337 (0.262 to 0.432) 0.003; 0.478 (0.296 to 0.772)
Elite HIV-controller status (n) % <0.001; 0.199 (0.151 to 0.263) <0.001; 0.264 (0.172 to 0.406)
HCV spontaneous clearance (n) % 0.029; 0.562 (0.335 to 0.943) 0.010; 0.503 (0.297 to 0.850)
HLA-B*57 (n) % 0.004; 0.446 (0.256 to 0.779)
p values < 0.05 are shown in bold. CI, confidence interval; OR, odd ratio; PWID, people who inject drug.
aPatients were categorized according to the median age at diagnosis; 29.4 [24.6 to 35.4]; bpatients were categorized according to the median
CD4+ T-cell nadir; 447 [304 to 622].
Dominguez-Molina B et al. Journal of the International AIDS Society 2020, 23:e25607
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25607/full | https://doi.org/10.1002/jia2.25607
7
cohorts [10,11], were mainly due to the contribution of persis-
tent but not transient HIV-controllers. This was true even
after adjusting by elite controller status subset that was
enriched in persistent controllers and when considering the
loss of virological control instead of the loss of HIV-controller
status. As expected, we had an overrepresentation of HLA-
B*57 carriers among HIV-controllers, which has been exten-
sively reported [25–27]. Some authors have previously
observed higher HCV clearance among patients who carried
HLA-B*57 alleles [28]. Nevertheless, we did not find an asso-
ciation of HLA-B*57 with HCV spontaneous clearance neither
in HIV-controllers (persistent or transient, p = 0.2; 2.6 [0.6 to
11.8] and p = 0.6; 1.6 [0.3 to 7.4] respectively) nor HIV non-
controllers separately (p = 0.3; 1.6 [0.7 to 3.6]). Asher et al.,
have communicated that other factors besides HLA-B*57,
such as HIV spontaneous control, were associated with HCV
spontaneous clearance [29] in agreement with our results.
In the present study we found no differences in HCV geno-
type distribution between persistent and transient HIV-con-
trollers, while we found a different HCV genotype distribution
in the overall HIV-controller population vs. non-controllers
[12]. Therefore, the most plausible explanation for this fact is
that HIV-controllers spontaneously cleared genotype 1 more
easily than non-controllers, as it occurs in general population
[30]. Unfortunately we did not have enough subjects in acute
HCV infection in order to know HCV-genotype preferential
clearance in HIV-controllers.
This study describes a new attribute of persistent HIV-con-
trollers, which is the enhanced capacity in people living with
HIV to clear other chronic viral infection as HCV. Persistent
controllers, that have special characteristics, in the case of
supercontrollers, consisting on an enhance T-cell response
[23], a specific proteomic and metabolomic profile [8,9], low
levels of inflammation [4] and very low viral diversity and
reservoir, absence of viral evolution [4] make these extraordi-
nary subjects an exceptional model of persistent viral remis-
sion, that overlap largely with the described exceptional elite
controllers [31–33] or even with a model of HIV eradication.
In fact, the provocative hypothesis of whether some of these
subjects have been able to eradicate HIV needs to be proven.
We encountered several limitations while performing this
work such as the low number of HLA-B*57 typed patients,
responsible for the loss of statistical power in multivariate
analysis and that we were unable to include data on IL28B
genotype and liver fibrosis. However, this is the largest HIV-
controller cohort analysed in relation to HCV exposition pro-
file and that differentiates between persistent and transient
HIV-controllers that have allowed us to analyse the associa-
tion of spontaneous HCV clearance with persistent HIV-con-
troller status. These analyses were not possible in other
published HIV-controller cohorts.
5 | CONCLUSIONS
This study shows an association between spontaneous persis-
tent HIV-control and HCV spontaneous clearance. The study
findings support the idea of preserved immune mechanisms in
persistent HIV control implicated in HCV spontaneous clear-
ance. These results highlight persistent HIV-controllers but
not transient controllers as a good model of functional HIV
cure.
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